AUTL Autolus Therapeutics PLC

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November.

Truist Securities BioPharma Symposium Panel: Considerations for an Oncology Company’s Autoimmune Side HustleDate and time: 9 November 2023, 11:40am ET / 16:40pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Jefferies London Healthcare Conference   Fireside ChatDate and time: 16 November 2023, 4:00am ET / 9:00am GMTLocation: London, UKPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Piper Sandler 35th Annual Healthcare Conference Fireside ChatDate and time: 28 November 2023, 11:30am ET/ 16:30pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics

Find out more information about upcoming events and any webcast and replay details at: https://www.autolus.com/investor-relations/events/

About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:

Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com

Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com

Lauren WilliamsInvestase+44 23 9438 7760lauren@investase.com